38 results on '"Otterson, G.A."'
Search Results
2. P1.21-15 Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab
3. EP13.05-01 Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide
4. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
5. EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial
6. OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.
7. EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping
8. 78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors
9. EP.12A.04 Patterns of Osimertinib Dose-Reduction and Impact on Outcomes in EGFR-Mutation Positive Non-Small Cell Lung Cancer
10. P3.13C.04 Assessing ctDNA using a Methylation-informed Molecular Response Algorithm in Extensive-Stage Small Cell Lung Cancer Patients
11. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
12. 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up
13. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study
14. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
15. Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”
16. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors
17. 67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
18. 540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
19. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer
20. A pilot trial of G3139, a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer
21. Immune related adverse events across cancer types: Incidence, risk factors and survival
22. End of life resource utilization among patients receiving immunotherapy for advanced cancer
23. PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer
24. 1772P - Immune related adverse events across cancer types: Incidence, risk factors and survival
25. 1527P - End of life resource utilization among patients receiving immunotherapy for advanced cancer
26. An epigenetic mechanism for capecitabine resistance in mesothelioma
27. Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
28. Phase 2 Trial of Nab-Paclitaxel Plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding From VEGF Directed Therapies
29. Comparative Effectiveness of Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)
30. Protein Arginine Methyltransferase-5 as a Novel Epigenetic Target in Lung Cancer
31. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines
32. 557 PRMT5, a Novel Epigenetic Target in Lung Cancers
33. PCN121 ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): AN ANALYSIS FROM THE NCCN ONCOLOGY OUTCOMES DATABASE
34. RT-PCR Heteroduplex Analysis Permits Differentiation of Transgene and Host Gene Expression in a Transgenic Animal Model
35. Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC)
36. Stch encodes the ‘ATPase core’ of a microsomal stress 70 protein.
37. Functional analysis at the Cys706 residue of the retinoblastoma protein.
38. 615 Preliminary results of a phase I/II study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.